Short-duration, high-dose urokinase infusion for recanalization of occluded saphenous aortocoronary bypass grafts.
Thrombolytic recanalization of arterial bypass grafts has been pursued aggressively in the peripheral circulation but not in the coronary circulation. In an attempt to apply peripheral transcatheter thrombolytic techniques to the coronary circulation, nine patients with 10 occluded saphenous aortocoronary bypass grafts underwent recanalization procedures using a short-duration, high-dose urokinase infusion. Urokinase was infused at the occluded graft orifice at a rate of 600 units/min. The average infusion time was 1 hr, 26 min. The average urokinase dose was 435,000 units. Graft recanalization was achieved in eight (80%) of 10 grafts, although only six (60%) of 10 grafts were widely patent at the end of the procedure. All successfully recanalized grafts required balloon angioplasty of underlying stenoses. No complications, specifically myocardial infarction or cerebrovascular accident, were encountered. We have shown that occluded aortocoronary bypass grafts can be recanalized successfully by using a short-duration, high-dose urokinase infusion. It appears that, with attention given to angiographic techniques that minimize clot manipulation, recanalization can be accomplished safely in a majority of cases.
Marx
M
M
Department of Radiology, Pacific Presbyterian Medical Center, San Francisco, CA 94120.
Armstrong
W P
WP
Wack
J P
JP
Bernstein
R M
RM
Brent
B
B
Francoz
R
R
Gregoratos
G
G
D000328:Adult; D000368:Aged; D001026:Coronary Artery Bypass; D004334:Drug Administration Schedule; D005260:Female; D006083:Graft Occlusion, Vascular / Q000628:therapy*; D006801:Humans; D007261:Infusions, Intra-Arterial / Q000009:adverse effects; D008297:Male; D008480:Mediastinitis / Q000209:etiology; D008875:Middle Aged; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage*
D014568:Urokinase-Type Plasminogen Activator